Fosaprepitant Dimeglumine Suppliers & Bulk Manufacturers
Available Forms: Injection (IV)
Available Strengths: 150 mg/vial
Reference Brands: Emend® IV (EU & US)
Category: Oncology Cancer Care
Fosaprepitant Dimeglumine is available in Injection (IV) and strengths such as 150 mg/vial. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Fosaprepitant Dimeglumine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Fosaprepitant Dimeglumine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Fosaprepitant Dimeglumine is a trusted NK1 receptor antagonist used in oncology supportive care to prevent chemotherapy-induced nausea and vomiting (CINV). Available as a 150 mg intravenous injection, Fosaprepitant is commonly co-administered with 5-HT3 antagonists and corticosteroids. It enhances patient comfort and compliance during highly or moderately emetogenic chemotherapy. Approved in both the US and EU, and marketed under Emend® IV and as generics, it is widely used in hospital oncology departments and pharma B2B distribution. Reliable and effective, Fosaprepitant plays a critical role in managing CINV, improving quality of life for cancer patients receiving chemotherapy.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
